Director Molecular & Cellular Immunology
Stylus Medicine
Director Molecular & Cellular Immunology
Stylus Medicine
In vivo genome editing for CAR-T
About Stylus Medicine:
Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company’s approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.
About the Role:
Stylus Medicine is seeking an innovative, intellectually curious, and team-oriented Director, Molecular & Cellular Immunology to apply their deep immunology expertise and problem-solving abilities to collaboratively develop non-viral in vivo CART therapies. Reporting to the SVP, Immunology, this individual will lead the Molecular & Cellular Immunology team, with accountability for the execution of in vitro workflows in support of deepening our mechanistic understanding of the Stylus platform applied to immune cells, innovating within the platform, progressing the lead CART program to development candidate nomination, and preparing for advancement to clinic. This role is expected to serve as a close scientific thought partner with the SVP of Immunology, an effective collaborator with members of the broader scientific team, and a key driver in our mission to revolutionize the field of in vivo immune therapy.
Key Responsibilities & Accountabilities:
Qualifications & Skills:
Pay Range: $225,000-$240,000
In vivo genome editing for CAR-T
Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.
Explore more opportunities at Stylus Medicine